<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202893">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448201</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0306</org_study_id>
    <secondary_id>P30CA016086</secondary_id>
    <secondary_id>UNC-LCCC-0306</secondary_id>
    <secondary_id>CDR0000549851</secondary_id>
    <nct_id>NCT00448201</nct_id>
  </id_info>
  <brief_title>Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease</brief_title>
  <acronym>LCCC 0306</acronym>
  <official_title>Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a
      donor stem cell transplant helps stop the growth of cancer and abnormal cells. It also helps
      stop the patient's immune system from rejecting the donor's stem cells. The donated stem
      cells may replace the patient's immune cells and help destroy any remaining cancer or
      abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor
      can also make an immune response against the body's normal cells. Immunosuppressive therapy
      may improve bone marrow function and may be an effective treatment for hematologic cancer or
      other disease.

      PURPOSE: This clinical trial is studying the side effects and how well giving busulfan and
      fludarabine with or without antithymocyte globulin followed by donor stem cell transplant
      works in treating patients with hematologic cancer or other disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the clinical efficacy and toxicity profiles of a nonmyeloablative preparative
           regimen comprising busulfan and fludarabine with or without anti-thymocyte globulin
           followed by allogeneic hematopoietic stem cell transplantation in patients with
           hematologic cancers or other diseases.

        -  Determine the feasibility of this regimen in these patients.

        -  Establish a treatment-related mortality during the first 6 months that is less than 20%
           in patients treated with this regimen.

      Secondary

        -  Determine the response rates (disease-specific partial response and complete response)
           in patients treated with this regimen.

        -  Determine overall and progression-free survival of patients treated with this regimen.

        -  Determine the percent donor chimerism and immunologic recovery, including dendritic
           cell recovery, in patients treated with this regimen.

        -  Determine the risk of acute and chronic graft-versus-host disease and other toxicities
           in patients treated with this regimen.

        -  Assess the overall nonhematologic grades 3 and 4 toxicity of this regimen, including
           the incidence of veno-occlusive disease and pulmonary toxicity, in these patients.

      OUTLINE: Patients are assigned to 1 of 4 treatment groups according to disease type and
      donor type.

        -  Preparative regimen:

             -  Group 1 (patients with acute myeloid leukemia [AML], acute lymphoblastic leukemia
                [ALL], IPSS [International Prognostic Scoring System score] high-risk
                myelodysplastic syndromes [HR MDS], or chronic myelogenous leukemia [CML] with an
                HLA-matched related donor [MRD]): Patients receive fludarabine phosphate IV over
                30 minutes on days -7 to -3 and busulfan IV continuously over 48 hours on days -6
                and -5.

             -  Group 2 (patients with AML, ALL, IPSS HR MDS, or CML with an HLA-matched unrelated
                donor [MUD] or mismatched related donor [MMRD]): Patients receive fludarabine
                phosphate and busulfan as in group 1 and anti-thymocyte globulin IV over 4 hours
                on day -8.

             -  Group 3 (patients with all other diseases with a MRD): Patients receive
                fludarabine phosphate and busulfan as in group 1 and anti-thymocyte globulin as in
                group 2.

             -  Group 4 (patients with all other disease with a MUD or MMRD): Patients receive
                fludarabine phosphate and busulfan as in group 1 and anti-thymocyte globulin IV
                over 4 hours on days -8 and -7.

        -  Allogeneic stem cell transplantation: All patients undergo allogeneic peripheral blood
           stem cell transplantation on day 0. Patients then receive sargramostim (GM-CSF)
           subcutaneously once daily beginning on day 5 (groups 1 and 2) or day 7 (groups 3 and 4)
           and continuing until blood counts recover.

        -  Graft-vs-host disease (GVHD) prophylaxis: All patients receive oral tacrolimus twice
           daily on days -1 to 120 followed by a taper until day 180. Patients in groups 1 and 2
           also receive methotrexate IV on days 1, 3, and 6.

        -  Donor lymphocyte infusion (DLI): After day 120, patients with progressive disease or
           stable disease while off immunosuppression and with no evidence of active GVHD may
           receive DLI. Treatment with DLI may repeat every 8 weeks for up to 3 total infusions in
           the absence of disease response or GVHD.

      Peripheral blood and/or bone marrow samples are collected at baseline and then at 30, 60,
      90, 120, and 180 days post-transplantation. Chimerism (including the following subsets:
      whole blood, T-cells as defined by CD3 positivity, B-cells as defined by CD19 positivity,
      and myeloid cells as defined by CD14 and CD15 positivity) is analyzed by polymerase chain
      reaction technology.

      After restaging between Days 90 and 100 and between Days 150 to 180, patients are followed
      every 6 months for 1 years and then yearly for a maximum of 5 years from study entry.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response at 6 and 12 months post-transplant</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete or mixed donor chimerism at 30, 60, and 90 days post-transplant</measure>
    <time_frame>Days 30, 60, and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival</measure>
    <time_frame>Year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-vs-host disease at 6 months post-transplant</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD Prophylaxis with Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD prophylaxis with ATG + Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD prophylaxis with 2 doses ATG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Doses ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GVHD prophylaxis with 3 doses ATG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)</description>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>GM-CSF 500 ug QD subcutaneously will be given to recipients who remain with an ANC &lt; 1000/uL past day 20</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>A minimum total CD34+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>fludarabine 30 mg/m^2/day x 5 days IVPB over 30 minutes on Days -7 through -3</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Methotrexate 5 mg/m^2 per day on days +1, +3 and +6</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Suggested starting dose is 0.03 mg/kg po bid starting on Day -1</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0</description>
    <arm_group_label>Methotrexate Only Arm</arm_group_label>
    <arm_group_label>2 Doses ATG + Methotrexate</arm_group_label>
    <arm_group_label>2 Doses ATG</arm_group_label>
    <arm_group_label>3 Doses ATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Chronic lymphocytic leukemia (CLL), meeting the following criteria:

                    -  Absolute lymphocyte count &gt; 5,000/mm³

                    -  Lymphocytes must appear morphologically mature with &lt; 55% prolymphocytes

                    -  Lymphocyte phenotype with expression of CD19 and CD5

               -  Prolymphocytic leukemia (PLL), meeting the following criteria:

                    -  Absolute lymphocyte count &gt; 5,000/mm³

                    -  More than 55% prolymphocytes

                    -  Morphologically diagnosed

               -  Chronic myelogenous leukemia (CML), meeting the following criteria:

                    -  Diagnosis of CML or similar myeloproliferative disorders based on t(9;22)
                       or related t(9;12) cytogenetic abnormalities AND characterized by elevated
                       WBC counts in peripheral blood or bone marrow

                    -  In first chronic phase CML and a candidate for treatment with reduced-dose
                       busulfan

                    -  Patients with other cytogenetic abnormalities, such as t(9;12), that are
                       associated with an aggressive clinical course are eligible

               -  Non-Hodgkin's lymphoma (NHL), meeting the following criteria:

                    -  Any WHO class histologic subtype allowed

                    -  Core biopsies are acceptable provided they contain adequate tissue for
                       primary diagnosis and immunophenotyping

                    -  Bone marrow biopsies as sole means of diagnosis are not allowed for
                       follicular lymphoma

               -  Hodgkin's lymphoma, meeting the following criteria:

                    -  Any WHO class histologic subtype allowed

                    -  Core biopsies are acceptable provided they contain adequate tissue for
                       primary diagnosis and immunophenotyping

               -  Multiple myeloma, meeting the following criteria:

                    -  Active disease requiring treatment (Durie-Salmon stages I, II, or III)

               -  Acute myeloid leukemia with documented control, defined as &lt; 10% bone marrow
                  blasts and no circulating blasts

               -  Acute lymphoblastic leukemia, meeting the following criteria:

                    -  In early first relapse or beyond OR in first complete remission and has 1
                       of the following high-risk features:

                         -  t(9;22) or t(4;11)

                         -  WBC count &gt; 30,000/mm³ at presentation

                         -  Non-T-cell phenotype

                         -  More than 30 years of age

               -  Agnogenic myeloid metaplasia/myelofibrosis

                    -  Patients who are transfusion dependent or who have evolving myelodysplastic
                       or leukemic features or high-risk cytogenetic abnormalities are eligible

               -  Myelodysplastic syndromes (MDS) as defined by WHO criteria

          -  Meets 1 of the following criteria:

               -  Over 55 years of age

               -  Ineligible for busulfan-based therapy based on diminished organ function or poor
                  performance status

               -  Indolent and chemotherapy-responsive CLL, low-grade NHL, small lymphocytic
                  lymphoma, or PLL

          -  Patients who have undergone prior autologous stem cell transplantation are
             preferentially enrolled on clinical trial CALGB-100002, if available and patient is
             eligible

          -  HLA-matched or mismatched related donor or HLA-matched unrelated donor available

               -  HLA-identical sibling (6/6 or 9/10) (minimal serologic typing required for class
                  I [A, B]; molecular typing required for class II [DRB1])

               -  9/10 matched unrelated donor (MUD) (molecular analysis at HLA A, B, C, DRB1, and
                  DQB1 by high resolution typing required)

               -  5/6 MUD (molecular analysis at HLA A, B, and DRB1 required)

               -  No syngeneic donors

        PATIENT CHARACTERISTICS:

          -  Creatinine clearance ≥ 40 mL/min

          -  Bilirubin ≤ 3 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  DLCO &gt; 40% with no symptomatic pulmonary disease

          -  LVEF ≥ 30% by MUGA

          -  No uncontrolled diabetes mellitus or active serious infection

          -  No known hypersensitivity to Escherichia coli-derived products

          -  No HIV infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy, radiotherapy (except prophylactic cranial
             x-ray therapy), or surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C. Shea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 23, 2015</lastchanged_date>
  <firstreceived_date>March 14, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
